Today, the Cystic Fibrosis Foundation announced a new award of up to $2 million to Eloxx Pharmaceuticals Inc. to support the global Phase 2 clinical program of ELX-02, a potential therapy to treat people with cystic fibrosis who have nonsense mutations.
Site Search
Showing 11 - 20 of 78 results
Press Release
|
Feb. 4, 2008
|
6 min read
Press Release
|
Oct. 3, 2005
|
5 min read
Press Release
|
Jan. 18, 2006
|
3 min read
Press Release
|
July 16, 2008
|
5 min read
Press Release
|
June 13, 2021
|
4 min read
Today, the Cystic Fibrosis Foundation announced that it has awarded up to $400,000 to Life Edit Therapeutics Inc. to explore the application of their unique gene editing technology in CF.
Press Release
|
Sept. 23, 2021
|
3 min read
Funding will support improved detection, diagnosis, prevention, and treatment of infections related to cystic fibrosis.
Press Release
|
Oct. 18, 2018
|
4 min read
New funding will support clinical development of two novel therapies to address complications of cystic fibrosis
Press Release
|
Sept. 10, 2021
|
3 min read
Potential treatment from Calithera Biosciences minimizes growth of germs in the lungs
Press Release
|
Nov. 2, 2020
|
3 min read
Nonprofit commits $20 million to fund projects and accelerate genetic therapies for CF
Press Release
|
Aug. 5, 2020
|
4 min read